 Interferon Type I
"Interferon Type I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA).
| Descriptor ID |
D007370
|
| MeSH Number(s) |
D12.644.276.374.440.890 D12.776.467.374.440.890 D23.529.374.440.890
|
| Concept/Terms |
Interferon Type I- Interferon Type I
- Type I Interferons
- Interferons, Type I
- Interferons Type I
- Type I Interferon
- Interferon, Type I
|
Below are MeSH descriptors whose meaning is more general than "Interferon Type I".
Below are MeSH descriptors whose meaning is more specific than "Interferon Type I".
This graph shows the total number of publications written about "Interferon Type I" by people in this website by year, and whether "Interferon Type I" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 | | 1996 | 1 | 0 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 2 | 0 | 2 | | 1999 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2006 | 2 | 0 | 2 | | 2007 | 2 | 0 | 2 | | 2008 | 1 | 0 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 3 | 1 | 4 | | 2011 | 5 | 1 | 6 | | 2012 | 2 | 1 | 3 | | 2013 | 3 | 0 | 3 | | 2014 | 3 | 2 | 5 | | 2015 | 1 | 1 | 2 | | 2016 | 3 | 0 | 3 | | 2017 | 2 | 2 | 4 | | 2018 | 2 | 2 | 4 | | 2019 | 2 | 2 | 4 | | 2020 | 2 | 3 | 5 | | 2021 | 5 | 1 | 6 | | 2022 | 4 | 1 | 5 | | 2023 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Interferon Type I" by people in Profiles.
-
Graham ME, Merrick C, Akiyama BM, Szucs MJ, Leach S, Kieft JS, Beckham JD. Zika virus dumbbell-1 structure is critical for sfRNA presence and cytopathic effect during infection. mBio. 2023 Aug 31; 14(4):e0110823.
-
Tadepalli S, Clements DR, Saravanan S, Arroyo Hornero R, L?dtke A, Blackmore B, Paulo JA, Gottfried-Blackmore A, Seong D, Park S, Chan L, Kopecky BJ, Liu Z, Ginhoux F, Lavine KJ, Murphy JP, Mack M, Graves EE, Idoyaga J. Rapid recruitment and IFN-I-mediated activation of monocytes dictate focal radiotherapy efficacy. Sci Immunol. 2023 06 02; 8(84):eadd7446.
-
Halloran KM, Stenhouse C, Moses RM, Kramer AC, Sah N, Seo H, Lamarre SG, Johnson GA, Wu G, Bazer FW. The ovine conceptus utilizes extracellular serine, glucose, and fructose to generate formate via the one carbon metabolism pathway. Amino Acids. 2023 Jan; 55(1):125-137.
-
Sertznig H, Roesmann F, Wilhelm A, Heininger D, Bleekmann B, Elsner C, Santiago M, Schuhenn J, Karakoese Z, Benatzy Y, Snodgrass R, Esser S, Sutter K, Dittmer U, Widera M. SRSF1 acts as an IFN-I-regulated cellular dependency factor decisively affecting HIV-1 post-integration steps. Front Immunol. 2022; 13:935800.
-
Riella CV, McNulty M, Ribas GT, Tattersfield CF, Perez-Gill C, Eichinger F, Kelly J, Chun J, Subramanian B, Guizelini D, Alper SL, Pollak MR, Sampson MG, Friedman DJ. ADAR regulates APOL1 via A-to-I RNA editing by inhibition of MDA5 activation in a paradoxical biological circuit. Proc Natl Acad Sci U S A. 2022 11; 119(44):e2210150119.
-
Basavappa MG, Ferretti M, Dittmar M, Stoute J, Sullivan MC, Whig K, Shen H, Liu KF, Schultz DC, Beiting DP, Lynch KW, Henao-Mejia J, Cherry S. The lncRNA ALPHA specifically targets chikungunya virus to control infection. Mol Cell. 2022 10 06; 82(19):3729-3744.e10.
-
Zuo D, Chen Y, Cai JP, Yuan HY, Wu JQ, Yin Y, Xie JW, Lin JM, Luo J, Feng Y, Ge LJ, Zhou J, Quinn RJ, Zhao SJ, Tong X, Jin DY, Yuan S, Dai SX, Xu M. A hnRNPA2B1 agonist effectively inhibits HBV and SARS-CoV-2 omicron in vivo. Protein Cell. 2023 01; 14(1):37-50.
-
Rawat K, Tewari A, Morrisson MJ, Wager TD, Jakubzick CV. Redefining innate natural antibodies as important contributors to anti-tumor immunity. Elife. 2021 10 05; 10.
-
van der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, Lee DS, Greenland JR, Sun Y, Perez R, Ogorodnikov A, Ward A, Mann SA, Lynch KL, Yun C, Havlir DV, Chamie G, Marquez C, Greenhouse B, Lionakis MS, Norris PJ, Dumont LJ, Kelly K, Zhang P, Zhang Q, Gervais A, Le Voyer T, Whatley A, Si Y, Byrne A, Combes AJ, Rao AA, Song YS, Fragiadakis GK, Kangelaris K, Calfee CS, Erle DJ, Hendrickson C, Krummel MF, Woodruff PG, Langelier CR, Casanova JL, Derisi JL, Anderson MS, Ye CJ. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci Transl Med. 2021 Sep 22; 13(612):eabh2624.
-
Vazquez SE, Bastard P, Kelly K, Gervais A, Norris PJ, Dumont LJ, Casanova JL, Anderson MS, DeRisi JL. Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma. J Clin Immunol. 2021 08; 41(6):1169-1171.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|